Key result
Biochemical markers of NAFLD and NASH, including cytokeratin-18 fragments, offer tremendous potential to alter management strategies and monitor disease activity.
Biochemical markers have tremendous potential to alter management strategies and monitor disease activity in NAFLD and NASH, overcoming the limitations of liver biopsy.
Nonalcoholic fatty liver disease (NAFLD) remains a leading cause of chronic liver disease. In the context of NAFLD, the presence of nonalcoholic steatohepatitis (NASH) portends an adverse prognosis with greater risk of liver fibrosis and cirrhosis. Although liver biopsy is the keystone of patient management in NAFLD, it is also increasingly clear that such evaluation has its limitations. The availability of biochemical markers of NAFLD and NASH has tremendous potential to radically alter management strategies for these conditions, as well as to monitor disease activity. Our article provides an overview of biomarker discovery and selection in the setting of NAFLD and highlights future directions in the field.
No takes yet. Share an insight, caveat, or question.
Yılmaz et al. (2009) conducted a review in Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). Biochemical markers (e.g., Cytokeratin-18 fragments) was evaluated. Biochemical markers of NAFLD and NASH, including cytokeratin-18 fragments, offer tremendous potential to alter management strategies and monitor disease activity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: